BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

OriGene Technologies Reaches 3000 TrueMABâ„¢ Monoclonal Antibodies


7/28/2011 11:49:33 AM

3000HighlyValidatedMonoclonal Antibodies Made AgainstNative ProteinEpitopesExpands OriGene'sAntibodyPortfolio toOver7500

ROCKVILLE, Md., July 28, 2011 /PRNewswire-USNewswire/ --OriGeneTechnologies, Inc.a gene-centric life sciences company, today announced that through its July release, the TrueMAB monoclonal antibodies have reached the 3000 product milestone. Each TrueMAB, made against antigens produced mostly in HEK293T cells, has proven superior in performance for immunoassays that are sensitive to proteins' native conformations. The development further expands the company's overall monoclonal and polyclonal antibody offering to over 7500 in total.

Available immediately at http://www.origene.com/Antibody/TrueMAB/, this new addition of TrueMAB brand antibodies supports OriGene's commitment to building the largest and most specific monoclonal antibody portfolio in the world. Each antibody has been comprehensively tested in multiple applications including IHC, IF, IP, Flow and WB. "The extensive validation and exceptional performance of our TrueMAB monoclonal antibodies allows us to provide quality products to meet the critical research and diagnostic needs of our customers," commented Wei-Wu He, Ph.D., CEO & Chairman, OriGene Technologies. "We are proud of achieving this milestone in just two years."

Further TrueMAB Monoclonal Antibody product and ordering information can be found online athttp://www.origene.com/Antibody/TrueMAB/.

AboutOriGeneTechnologies

OriGene Technologies, Inc., is a gene-centric life sciences company dedicated to support academic, pharmaceutical and biotech companies in their research of gene functions and drug discovery. OriGene develops proteins, antibodies, and other molecular tools to allow researchers to analyze their data on a multiplex level. OriGene's novel product line includes the world's largest cDNA and shRNA clone collections, over 5,000 purified human proteins, high quality monoclonal antibodies (TrueMAB),100,000 highly validated human tissues, and protein microarray products and services. OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from our tissue collection. For more information, visit www.origene.com.

TrueMAB is a trademark of OriGene Technologies, Inc.

SOURCE OriGene Technologies, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES